Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling

Cell Cycle

Volumn 7, Issue 7, 2008, Pages 917-924

  Jamshidi, Farnaz ^a   Zhang, Jing ^a   Harrison, Jonathan S ^b   Wang, Xuening ^a   Studzinski, George P ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Acetyl salicylic acid; Cox inhibitors; Differentiation; Leukemia; MEK ERK pathway; Raf1; Vitamin D

Indexed keywords

ACETYLSALICYLIC ACID; CALCITRIOL; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P90; RAF PROTEIN; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER SUSCEPTIBILITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CHEMOPROPHYLAXIS; DRUG POTENTIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONOCYTE; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION;

EID: 42449162971     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.7.5620     Document Type: Article

References (50)

1. 3 that resist metabolism through C-24 oxidation and C-3 epimerization pathways. Steroids 2001; 66:463-71.
2. 3 and participates in its anti-apoptotic effect and cell cycle control in differentiating HL60 cells. Cell Cycle 2006; 5:447-51.
3. Flanagan L, Packman K, Juba B, O'Neill S, Tenniswood M, Welsh J. Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol 2003; 84:181-92.
4. 3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res 2003; 63:1325-32.
5. Krishnan AV, Peehl DM, Feldman D. The role of vitamin D in prostate cancer. Recent Results Cancer Res 2003; 164:205-21.
6. Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res 2003; 164:273-88.
7. 3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells. Cell Cycle 2002; 1:410-5.
8. 3. J Natl Cancer Inst 1997; 89:1199-206.
9. 3 and its analogs. Exp Cell Res 2004; 298:339-58.
10. 3-induced differentiation of human leukemia HL60 cells. Exp Cell Res 2000; 258:425-37.
11. 3. Leukemia 1994; 8:595-604.
12. Sokoloski JA, Sartorelli AC. Induction of the differentiation of HL-60 promyelocytic leukemia cells by nonsteroidal anti-inflammatory agents in combination with low levels of vitamin D3. Leuk Res 1998; 22:153-61.
13. Das D, Arber N, Jankowski JA. Chemoprevention of colorectal cancer. Digestion 2007; 76:51-67.
14. Jimenez P, Garcia A, Santander S, Piazuelo E. Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option? Curr Pharm Des 2007; 13:2261-73.
15. Wang D, DuBois RN. Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle 2007; 6:682-5.
16. 3. J Cell Physiol 2004; 198:333-42.
17. 3-induced differentiation of HL60 cells but is not mediated by the MEK/ERK module. J Cell Physiol 2006; 209:253-60.
18. 3. Exp Cell Res 1996; 224:312-22.
19. Harris P, Ralph P. Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines. J Leukoc Biol 1985; 37:407-22.
20. Auwerx J. The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation. Experientia 1991; 47:22-31.
21. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW. Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol 2004; 65:470-8.
22. Burdan F, Dudka J, Szumilo J, Korobowicz A, Klepacz L. Prenatal effects of DuP-697-the irreversible, highly selective cyclooxygenase-2 inhibitor. Reprod Toxicol 2003; 17:413-9.
23. Dohi M, Sakata Y, Seki J, Namikawa Y, Fujisaki J, Tanaka A, Takasugi H, Motoyama Y, Yoshida K. The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor. Eur J Pharmacol 1993; 243:179-84.
24. Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol 1971; 231:237-9.
25. Wang X, Studzinski GP. Inhibition of p38MAP kinase potentiates the JNK/SAPK pathway and AP-1 activity in monocytic but not in macrophage or granulocytic differentiation of HL60 cells. J Cell Biochem 2001; 82:68-77.
26. Tanaka T, Kurose A, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. Nitrogen oxide-releasing aspirin induces histone H2AX phosphorylation, ATM activation and apoptosis preferentially in S-phase cells: involvement of reactive oxygen species. Cell Cycle 2006; 5:1669-74.
27. Tavera Mendoza LE, Wang TT, White JH. p19INK4D and cell death. Cell Cycle 2006; 5:596-8.
28. 3 or all-trans-retinoic acid. Exp Cell Res 2001; 266:126-34.
29. Griffin JD, Ritz J, Nadler LM, Schlossman SF. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest 1981; 68:932-41.
30. Bunce CM, Mountford JC, French PJ, Mole DJ, Durham J, Michell RH, Brown G. Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketoreductase family. Biochim Biophys Acta 1996; 1311:189-98.
31. 3-induced differentiation of HL60 cells. J Cell Biochem 2001; 80:471-82.
32. Marcinkowska E. Evidence that activation of MEK1,2/erk1,2 signal transduction pathway is necessary for calcitriol-induced differentiation of HL-60 cells. Anticancer Res 2001; 21:499-504.
33. Zhang J, Posner GH, Danilenko M, Studzinski GP. Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway. J Steroid Biochem Mol Biol 2007; 105:140-9.
34. Spalding WM, Reeves MJ, Whelton A. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs. Am J Ther 2007; 14:3-12.
35. Howes LG, Krum H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drug Saf 2002; 25:829-35.
36. Meagher EA. Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications. Drug Saf 2003; 26:913-24.
37. Moreno J, Krishnan AV, Peehl DM, Feldman D. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res 2006; 26:2525-30.
38. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005; 65:7917-25.
39. Marcinkowska E, Kutner A. Side-chain modified vitamin D analogs require activation of both PI 3-K and erk1,2 signal transduction pathways to induce differentiation of human promyelocytic leukemia cells. Acta Biochim Pol 2002; 49:393-406.
40. Studzinski GP, Wang X, Ji Y, Wang Q, Zhang Y, Kutner A, Harrison JS. The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway. J Steroid Biochem Mol Biol 2005; 97:47-55.
41. 3 in human leukemia HL60 cells through a vitamin D response element in the 5′-flanking region. Oncogene 2006; 25:7078-85.
42. Wang X, Studzinski GP. Phosphorylation of raf-1 by kinase suppressor of ras is inhibited by "MEK-specific" inhibitors PD 098059 and U0126 in differentiating HL60 cells. Exp Cell Res 2001; 268:294-300.
43. 3 and is required for optimal cell differentiation. Exp Cell Res 2007; 313:3034-45.
44. Therrien M, Michaud NR, Rubin GM, Morrison DK. KSR modulates signal propagation within the MAPK cascade. Genes Dev 1996; 10:2684-95.
45. Therrien M, Chang HC, Solomon NM, Karim FD, Wassarman DA, Rubin GM. KSR, a novel protein kinase required for RAS signal transduction. Cell 1995; 83:879-88.
46. Roy F, Laberge G, Douziech M, Ferland-McCollough D, Therrien M. KSR is a scaffold required for activation of the ERK/MAPK module. Genes Dev 2002; 16:427-38.
47. Selvendiran K, Bratasz A, Tong L, Ignarro L, Kuppusamy P. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle 2008; 7.
48. Markaverich BM, Crowley J, Rodriquez M, Shoulars K, Thompson T. Tetrahydrofurandiol stimulation of phospholipase A2, lipoxygenase, and cyclooxygenase gene expression and MCF-7 human breast cancer cell proliferation. Environ Health Perspect 2007; 115:1727-31.
49. Gallego C, Gupta SK, Heasley LE, Qian NX, Johnson GL. Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and rat 1a cells. Proc Natl Acad Sci USA 1992; 89:7355-9.
50. Kyriakis JM, App H, Zhang XF, Banerjee P, Brautigan DL, Rapp UR, Avruch J. Raf-1 activates MAP kinase-kinase. Nature 1992; 358:417-21.